AMPH Q4 2018 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$90M+48.5% YoY

Gross Profit

$35M38.7% margin

Operating Income

$2M1.7% margin

Net Income

$2M2.1% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+18.7%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

-$65,000

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$514M

Total Liabilities

$149M

Stockholders' Equity

$332M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$60M	+48.5%
Gross Profit	$35M	$21M	+68.6%
Operating Income	$2M	-$2M	+192.8%
Net Income	$2M	$1M	+27.2%

Revenue Segments

Finished Pharmaceutical Products Segment

$83M100%